Advertisement

Topics

Companies Related to "Trial of Gemcitabine/Carboplatin With or Without BSI-201 (a PARP1 Inhibitor) in Patients With Previously Untreated Advanced Squamous Cell Lung Cancer" [Most Relevant Company Matches] - Page: 5 RSS

11:53 EDT 21st March 2019 | BioPortfolio

Here are the most relevant search results for "Trial of Gemcitabine/Carboplatin With or Without BSI-201 (a PARP1 Inhibitor) in Patients With Previously Untreated Advanced Squamous Cell Lung Cancer" found in our extensive corporate database of over 50,000 company records.

Showing "Trial Gemcitabine Carboplatin With Without PARP1 Inhibitor Patients" Companies 101–125 of 4,400+

Probably Relevant

Speedel

Speedel is a biopharmaceutical company that seeks to create value for patients, partners and investors by developing innovative therapies for cardiovascular and metabolic diseases. Speedel is a world leader in renin inhibition, a promising new approach with significant potential for treating cardiovascular diseases. Our lead product candidate SPP100 (Aliskiren), the first-in-class renin inhibitor,...


Stentys

Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents for the treatment of acute myocardial infarction. Founded by Jacques Séguin, M.D., Ph.D., (founder of CoreValve, which was acquired last year by Medtronic for $700 million) and by Gonzague Issenmann, Stentys received CE Mark of its flagship products in 2010 and will st...

X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and cancer. X4’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4’s most advanced product candidate, X4P-001, is in a Ph...


RapidTrials

RapidTrials is a clinical trial acceleratorIt is the industry’s only company exclusively focused on driving clinical trial performance at the site level, offering assistance and advocacy to research centers – directly and through their Sponsors and CROs. Founded in 1996, the company’s knowledge-based tools and custom advisory services help improve trial performance at every step of the devel...

Symphony Clinical Research®

Symphony Clinical Research®, formerly known as Clinical Resource Network, LLC (CRN), is the global service leader in providing in-home and alternate-site clinical services to patients in all phases and therapeutic areas of clinical trials. In-home services can be used in all patient populations from neonatal through geriatrics. Since 2003, Symphony's...

Auspex Pharmaceuticals, Inc.

Auspex Pharmaceuticals is a privately held biopharmaceutical company located in La Jolla, California. The company is a pioneer in the use of deuterium in medicinal chemistry, and is focused on the treatment of hyperkinetic movement disorders including Huntington’s disease, Tourette syndrome and tardive dyskinesia. Its lead compound, SD-809, is a novel ...

Life Time Pharmaceuticals Incorporated

LifeTime™ Pharmaceuticals, a private clinical-stage pharmaceutical company, focuses on the development of drugs that are safe enough for long-term, chronic administration. Compounds currently under development seek to eliminate and prevent recurrence of potentially fatal cancers and infectious syndromes. Human clinical trial results presented at several scientific meetings (see below) have shown...

Clinical Resource Network, LLC

Clinical Resource Network, LLC (CRN) is the global service leader in providing in-home and alternate-site clinical services to patients in all phases of clinical trials. Since 2003, CRN’s combined experience in clinical practices, project management, nursing and homecare has delivered a superior experience for sponsors, sites and patients. CRN's servi...

CBT Pharmaceuticals, Inc.

CBT Pharmaceuticals is a biopharmaceutical company focused on developing innovative oncology therapeutics harnessing the immune system and targeting specific molecular pathways to tame cancer. The company is advancing a pipeline of four development-stage assets. CBT-101, is an oral c-MET inhibitor targeting the epithelial to mesenchymal transition (EMT) pa...

The German Breast Group and Celgene Corporation

GBG is a large independent academic network of over 500 study centers in Germany with the world- wide largest experience in conducting neoadjuvant breast cancer trials. Since 1998, with joined forces from AGO-B, over 10.000 patients participated in the neoadjuvant “Gepardo” trial series. GBG has recruited at totality of over 35.000 patients to tr...

TP Therapeutics Inc.

TP Therapeutics is a clinical-stage precision oncology company forging a new path for targeted cancer care. Founded in October 2013 by Dr. J. Jean Cui, the lead inventor of Pfizer’s oncology drugs crizotinib and lorlatinib, the company is developing a pipeline of novel drugs that aim to tackle treatment resistance and give new hope to patients who have ...

NantBioScience

NantBioScience, a wholly-owned subsidiary of NantWorks, LLC, is a biopharmaceutical company focused on the discovery of innovative treatments by developing molecularly targeted drugs, based on the molecular profile of the patient's tumor, independent of the cancer's anatomical type. Dr. Patrick Soon-Shiong, the creator of Abraxane® and the founder of th...

NCRL

Founded in 1984 as the Nottingham Clinical Trial Data Centre, the Group has its origins in cardiology and statistics research in The University of Nottingham. As a commercial organisation, the Group has developed a broad range of sophisticated services and now supports clinical trial programmes ranging from small studies to international megatrials in many indications.

CBT Pharmaceuticals

CBT Pharmaceuticals is a life sciences company developing innovative oncology therapeutics targeting the growth and proliferation of cancer cells. The company is advancing a pipeline of four development-stage assets including CBT-101, an oral c-Met inhibitor targeting the epithelial-mesenchymal transition (EMT) pathway in cancers and CBT-501, a novel human...

SciClone Pharmaceuticals, Inc.

SciClone Pharmaceuticals (NASDAQ: SCLN) is a profit-driven, global specialty pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and overall expense manage...

Grid Therapeutics, LLC

Grid Therapeutics is a biotech company based on the innovative platform for discovering and isolating human derived antibodies. Dr Edward F. Patz, Jr, is the co-founder and CEO of Grid, located in Durham, North Carolina. The lead antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis. ...

Allos Therapeutics, Inc.

Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of FOLOTYN® (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in t...

Santarus, Inc. and Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST™ (RHUCIN® in non-European territories) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein. The product is also under development f...

NantCell

NantCell, a member of the NantWorks ecosystem of companies, is a biopharmaceutical company focused on the discovery of innovative molecularly targeted therapies based on the unique molecular profile of the patient's tumor, independent of the cancer's anatomical type. Dr. Patrick Soon-Shiong, the creator of Abraxane® and the founder of the nab® techno...

Puma Biotechnology, Inc.

Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those ...

eClinicalHealth Limited

Headquartered in Scotland, eClinicalHealth Limited, developers of the ClinpalTM remote research platform, was founded in 2012 to provide innovative clinical trial solutions. The company is committed to leading open and collaborative innovation discussions about patient-centric clinical trial processes and technology with pharmaceutical companies, CROs and ...

ClinicalStudyDataRequest.com

ClinicalStudyDataRequest.com is the industry leader in global clinical trial data transparency. Its multi-sponsor Request System provides a secure process for researchers to request access to global clinical trial data through a publicly available website. An Independent Review Panel and process overseen by the Wellcome Trust review data requests received ...

Entasis Therapeutics Holdings Inc.

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SU...

Celmatix

Celmatix, Inc. is a New York City-based biotechnology company targeting the reproductive medicine sector. The company aims to provide molecular diagnostic products and services to patients based on proprietary genetic biomarkers for infertility. Currently, infertility is diagnosed by a financially and emotionally costly process of trial and error. Celmatix aims to provide products and services to ...

MMG

MMG, a Ketchum company and part of the Omnicom Group (NYSE: OMC) family, is a global clinical trial patient recruitment and retention organization. With experience in more than 70 countries and deep insights across therapeutic areas, patient populations, and study types, MMG designs and executes strategic programs to increase and accelerate clinical trial participation for pharmaceutical industry ...


More From BioPortfolio on "Trial of Gemcitabine/Carboplatin With or Without BSI-201 (a PARP1 Inhibitor) in Patients With Previously Untreated Advanced Squamous Cell Lung Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks